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olympic medicine toward consequences of scientific progress" (1991b).
Performance-enhancing drugs have cast a long shadow on the modern Olympics. Whether the agents are the strychnine, heroin, cocaine, and morphine that athletes used in Athens in 1896 or the amphetamines, steroids, and erythropoietin that some use today, the dilemma remains the same. As a sports medicine specialist noted in 2004, the "attraction of performance-enhancing drugs is simply that they permit the fulfillment of the mythical promise of boundless athletic performance -the hubristic 'faster, higher, stronger' motto of the Olympic Games" (2004) . The ensuing systems of medical surveillance have led, inevitably, to "a new type of competition," in which some athletes try to stay one step ahead of the authorities (2001) .
The arms race will continue as medical science produces ever newer means of performance enhancement. Will future athletes try growth factors or gene therapy? 3 One thing is certain: the Olympics will remain an object of medical fascination.
Disclosure forms provided by the author are available with the full text of this article at NEJM.org.
T he National Quality Strategy of the U.S. Department of Health and Human Services broadly defines the outcomes that the Centers for Medicare and Medicaid Services (CMS) wants to achieve through the care it purchases for its beneficiaries. The strategy's three aims of better health, better care, and lower costs capture CMS's concept of valueimproved outcomes for individuals and populations at lower costs. CMS has many tools to support the three aims, but we believe that value-based purchasing (VBP) is one of the most potentially transformational. VBP rewards providers who deliver better outcomes in health and health care for the beneficiaries and communities they serve at lower cost. Unlike voluntary programs, such as the Shared Savings Program, VBP applies to nearly all providers in a given setting. Two programs are under way, and a third will begin next year (see box).
VBP VBP allows CMS to specify measures that best advance the National Quality Strategy's objectives. Measurement to date has focused primarily on clinical care processes, safety, and patient experience. In keeping with CMS's three aims, the scope of measurement will be expanded to include the objectives of better health for communities, care coordination, and lower costs. Six domains of measurement, corresponding to the National Quality Strategy's priorities, capture this expansion and are the basis for a proposed reorganization of VBP measures (see table) . A more comprehensive set of measures that includes costs, population health, and care coordination will help providers focus on the care and support available outside their walls. Use of these six domains to align quality measurement across settings will allow CMS to create shared accountability for performance. It increases the likelihood that VBP will move the needle in areas that have not previously been measured, and for which incentives have not been provided, on a national scale.
Five principles are important in developing the VBP portfolio further. First, programs must define the end goal, not the process for achieving it. The best way to improve outcomes with VBP is to measure patient-centered outcomes and provide incentives for achieving them. VBP programs' measure sets must clearly and parsimoniously define the most critical outcomes in health, health care, and cost for each setting. Core measure sets must measure similar aspects of care and health -such as care coordination, patient experience, functional status, and costs -uniformly across episodes and settings of care. Emphasizing patient-centered outcomes in VBP programs will allow providers to focus on a concise core set of measures in which they have the greatest opportunities for improvement without being unduly burdened with reporting. More important, outcome measures allow providers the flexibility to identify the most critical process or system improve- ments needed to improve outcomes. CMS can catalyze systemlevel thinking and improvement, but providers' innovation and action must be local. Second, all providers' incentives must be aligned. Reimbursement under a fee-for-service system is often siloed according to the type of provider and setting. VBP has the potential to harmonize types of measures and provider incentives across settings. For example, including incentives to reduce readmissions and spending per beneficiary for acute care hospitals, post-acute care facilities, and outpatient physicians establishes shared accountability and incentives to coordinate care. Alignment is also needed between government and private-sector VBP programs.
Third, the right measures must be developed and implemented in rapid cycle. VBP programs need to identify the set of measures that defines the kind of patientcentered care the health system should provide. In at least three of the National Quality Strategy's domains -care coordination, population health, and coststhere are gaps in currently available measures. Patient-reported functional outcomes, longitudinal measures, and measures that cut across the care continuum are lacking in multiple domains. Under the current model of measure development, endorsement, and implementation, it takes 4 or more years for a measure to be included in hospital VBP. We must collaborate to develop (or modify existing) measures to fill gaps and implement measures as quickly as possible while maintaining the review and publiccommenting processes.
Fourth, CMS must actively support quality improvement. VBP programs should reward improvement as well as overall achievement whenever possible, but incentives alone cannot improve quality. Providers need the knowledge and skills to identify opportunities and implement quality improvements. Quality Improvement Organizations are CMS-funded organizations that provide on-theground technical assistance to providers who require support in improving quality. Other examples of frontline support include the Community-Based Care Transitions program and Partnership for Patients.
Finally, the clinical community and patients must be actively engaged in VBP. VBP will improve care only when clinicians, provider organizations, and patients understand its goals, are engaged in active improvement, and make decisions on the basis of value. Federal VBP programs must collaborate with and leverage regional, state, and private-sector pay-for-performance programs that, in many cases, have already substantially improved quality.
Shifting to a culture of shared accountability for patient and community outcomes and costs will be a journey. VBP programs are a step in the transition from a fee-for-service health system to one that is fully accountable for these outcomes. Given the national scope of VBP programs, it is critical to monitor and evaluate their effects, make adjustments when needed, and provide support to providers and communities that are struggling with improvement. The United States needs a health system that achieves better health and better care at lower costs, and VBP is a potentially important tool for achieving those goals. In an atmosphere of austerity, demonstrating the cost-effectiveness of preventive health interventions becomes particularly important.
Although preventive approaches to disease are intuitively appealing -and frequently presented as a way to reduce costs -analyses have suggested that, as a whole, they're no more costeffective than therapeutic interventions. 1 But are some preventive approaches more cost-effective than others? The National Commission on Prevention Priorities attempted to address this question, ranking clinical preventive services in terms of cost-effectiveness and "clinically preventable burden" of disease. 2 Yet some preventive services, such as tobacco taxes or water fluoridation, are not delivered in health care settings. Understanding whether certain approaches are more costeffective than others requires a framework for categorizing preventive interventions.
Medicine Because reaching individuals directly is generally more expensive than changing an environmental element, we hypothesized that unless a person-directed intervention was very effective (like childhood immunization, for example), environmental interventions would generally be more cost-effective. We further hypothesized that it mattered where an intervention was delivered and that nonclinical, person-directed interventions would be more costeffective than clinical interventions. To test these hypotheses, we conducted a comparative analysis of the cost-effectiveness of environmental, nonclinical but person-directed, and clinical preventive interventions.
We analyzed the contents of the Tufts Medical Center CostEffectiveness Analysis (CEA) Registry, which contains information on 2815 cost-effectiveness analyses published through December 2011. Costs per quality-adjusted life-year (QALY, a unit of measure for survival that accounts for the effects of suboptimal health status) are reported after conversion to 2011º U.S. dollars. Only costutility analyses -which permit comparison of programs addressing different health problems by converting health outcomes into a common metric -are included in the registry. We excluded studies that didn't report on an intervention meet-
